The Association of the British Pharmaceutical Industry (ABPI) have welcomed the publication of a new ‘Roadmap for Progress on Combating Antimicrobial Resistance (AMR)’, by more than 13 global pharmaceutical companies (10 ABPI member companies).
Announced today at a UK Government Department of Health event, hosted as part of the United Nations (UN) General Assembly high-level meeting on AMR, the roadmap details fifteen specific actions companies will take forward. These actions cover measures to:
Today's roadmap for action from leaders in the global pharmaceutical industry builds upon January's Davos Declaration, and was a pledge to combat AMR beyond the 34 antibiotics and infection preventing vaccines already in the pharmaceutical industry's global pipeline. Over 100 companies and 13 associations from the pharmaceutical, biotechnology and diagnostics industries signed the Declaration.
As well as this announcement by industry, we also welcome the UN's General Assembly High-Level Declaration that sets out a strong national, regional and international political commitment that declared to address AMR comprehensively. This Declaration recognises the important role of Member States, non-governmental organizations, civil society, the private sector and academic institutions in working together as equal partners to increase and improve awareness of AMR.
Last week, the UK Government also published their official response to Lord O'Neill's Review on AMR.
Dr Virginia Acha, Executive Director, Research, Medical, Innovation said:
"Following Lord O'Neill's timely report in May, there has been a tidal wave of political and public momentum that's acknowledged resistance to antibiotics is one of the greatest global health threats of our time.
"The global pharmaceutical industry is on the crest of this wave, and today we have underlined our role as key player in the fight against drug resistance and in preventing the rise of the superbug.
"By detailing specific actions companies will take in a proactive, ambitious and comprehensive roadmap, our industry is showing that it is committed to be held to account, and our action should be commended by all.
"On top of this, the UN's General Assembly High-Level Declaration in New York, and on a local level by the UK Government last week, are also a welcome sign that this isn't simply a problem for 'big pharma' to resolve. Both rightly acknowledge that detecting, preventing and controlling resistance will require a strategic, coordinated, and sustained global and local response.
"Keeping antibiotics effective is everybody's responsibility, and in the UK, the ABPI and our members stand ready to work alongside policymakers, as well as the NHS, patients, healthcare providers, academia, the agricultural community and all global partners in this fight."
Background and further information
ABPI Press Office Email: email@example.com Telephone during work hours (9am to 5pm Monday to Friday): +44 (0) 20 7747 7147 or +44 (0) 20 7747 1441 Telephone out of hours (5pm to 9am and weekends): +44 (0) 20 7747 1445
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies supplying around 90 per cent of all medicines used by the NHS, and are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.